— Rick Grimes, Financial Lines Practice Leader, One80 Intermediaries
COVID-19 has had a profound impact on the life sciences sector, pushing many life science organizations to intensify their focus on digitization, artificial intelligence, and M&A activity. Further, organizations are seeing a significant increase in available data and reporting across the ecosystem.
I am confident that these changes will have positive impact on all facets of the life sciences industry; from preliminary research to clinical trials, to manufacturing and supply chain, to commercialization and enabling functions. These opportunities are also certain to advance medicine, testing, diagnostics, and next-generation therapies. But with these rapid levels of innovation come ever-changing insurance exposures.
One80’s life sciences specialists understand the considerable risk in which clinical testing, biotechnology, medical product manufacturing and other related practices are involved. From research and development to product commercialization and more, One80 can help you secure the insurance solutions your clients require through partnerships with market leading carriers. Coverage is available on admitted and non-admitted paper in all states and foreign jurisdictions. We offer claims coordination and both package and monoline coverages.
Click here to view more information on our life sciences coverage.
One80 Intermediaries, innovating at the pace of change.